SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) CEO Friedhelm Blobel sold 70,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $10.22, for a total value of $715,400.00. Following the completion of the sale, the chief executive officer now directly owns 102,637 shares of the company’s stock, valued at $1,048,950.14. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Friedhelm Blobel also recently made the following trade(s):

  • On Monday, November 14th, Friedhelm Blobel sold 30,000 shares of SciClone Pharmaceuticals stock. The shares were sold at an average price of $10.27, for a total value of $308,100.00.
  • On Thursday, October 27th, Friedhelm Blobel sold 40,000 shares of SciClone Pharmaceuticals stock. The shares were sold at an average price of $9.30, for a total value of $372,000.00.

Shares of SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) opened at 10.15 on Friday. SciClone Pharmaceuticals Inc. has a 12-month low of $7.36 and a 12-month high of $15.02. The firm has a market capitalization of $518.19 million, a PE ratio of 14.50 and a beta of 1.65. The stock has a 50 day moving average price of $9.78 and a 200 day moving average price of $11.26.

Insider Buying and Selling by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

A number of hedge funds have recently made changes to their positions in the stock. Municipal Employees Retirement System of Michigan raised its stake in shares of SciClone Pharmaceuticals by 0.3% in the third quarter. Municipal Employees Retirement System of Michigan now owns 47,180 shares of the specialty pharmaceutical company’s stock valued at $483,000 after buying an additional 120 shares in the last quarter. Suntrust Banks Inc. raised its stake in shares of SciClone Pharmaceuticals by 3.8% in the second quarter. Suntrust Banks Inc. now owns 11,938 shares of the specialty pharmaceutical company’s stock valued at $155,000 after buying an additional 432 shares in the last quarter. California State Teachers Retirement System raised its stake in shares of SciClone Pharmaceuticals by 0.7% in the third quarter. California State Teachers Retirement System now owns 105,784 shares of the specialty pharmaceutical company’s stock valued at $1,084,000 after buying an additional 700 shares in the last quarter. Nationwide Fund Advisors raised its stake in shares of SciClone Pharmaceuticals by 1.7% in the second quarter. Nationwide Fund Advisors now owns 41,262 shares of the specialty pharmaceutical company’s stock valued at $539,000 after buying an additional 708 shares in the last quarter. Finally, Citadel Advisors LLC raised its stake in shares of SciClone Pharmaceuticals by 3.4% in the third quarter. Citadel Advisors LLC now owns 42,407 shares of the specialty pharmaceutical company’s stock valued at $435,000 after buying an additional 1,400 shares in the last quarter. 81.03% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece was originally published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2016/11/25/friedhelm-blobel-sells-70000-shares-of-sciclone-pharmaceuticals-inc-scln-stock.html.

SciClone Pharmaceuticals Company Profile

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

5 Day Chart for NASDAQ:SCLN

Receive News & Stock Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.